Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Recruiting now · Phase 1/Phase 2
Conditions studied: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
In brief
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Multiple myeloma is a cancer that affects white blood cells called plasma cells, which are made in the bone marrow and are part of the immune system. Multiple myeloma cells have a protein on their surface called B-cell maturation antigen (BCMA) that allows the cancer cells to survive and grow. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Belantamab mafodotin has been designed to attach to the BCMA protein, which may cause the myeloma cell to become damaged and die. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Iberdomide plus belantamab mafodotin may help slow or stop the growth of cancer in patients with multiple myeloma.
Key facts
- Study ID
- NCT06232044
- Run by
- Alliance for Clinical Trials in Oncology
- People needed
- 88
- Starts
- 2025-04-23
- Expected to finish
- 2030-08-01
- Last updated by the study team
- 2026-08-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Marshfield Medical Center - Weston — Weston, Wisconsin, United States (enrolling)
- McFarland Clinic - Ames — Ames, Iowa, United States (enrolling)
- ProHealth Waukesha Memorial Hospital — Waukesha, Wisconsin, United States (enrolling)
- UW Cancer Center at ProHealth Care — Waukesha, Wisconsin, United States (enrolling)
- Mary Greeley Medical Center — Ames, Iowa, United States (enrolling)
- McFarland Clinic - Trinity Cancer Center — Fort Dodge, Iowa, United States (enrolling)
- McFarland Clinic - Marshalltown — Marshalltown, Iowa, United States (enrolling)
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana, United States (enrolling)
- Tufts Medical Center — Boston, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Coborn Cancer Center at Saint Cloud Hospital — Saint Cloud, Minnesota, United States (enrolling)
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Bergen — Montvale, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Commack — Commack, New York, United States (enrolling)
- Memorial Sloan Kettering Westchester — Harrison, New York, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- OhioHealth O'Bleness Hospital — Athens, Ohio, United States (enrolling)
- Columbus Oncology and Hematology Associates Inc — Columbus, Ohio, United States (enrolling)
- Riverside Methodist Hospital — Columbus, Ohio, United States (enrolling)
- Grant Medical Center — Columbus, Ohio, United States (enrolling)
- Doctors Hospital — Columbus, Ohio, United States (enrolling)
- Delaware Health Center-Grady Cancer Center — Delaware, Ohio, United States (enrolling)
- Grady Memorial Hospital — Delaware, Ohio, United States (enrolling)
- Columbus Oncology and Hematology Associates — Dublin, Ohio, United States (enrolling)
- Dublin Methodist Hospital — Dublin, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.